101
Participants
Start Date
February 29, 2016
Primary Completion Date
November 14, 2019
Study Completion Date
June 17, 2020
ticagrelor
Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
University of Florida, Jacksonville
University of Florida
OTHER